When 'retatrutide' isn't: what independent testing has found
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- No medicine containing retatrutide is approved anywhere. Every vial sold as retatrutide outside a Lilly trial is, at best, unapproved and, at worst, not what the label says.
- Buyer-submitted lab reports show both failures and high-purity passes, but buyers choose which vials to test and which results to publish.
- In Victoria, Australia, the health department reported six cases of acute liver injury after products labelled retatrutide, possibly from a contaminant; ABC News later reported seven hospitalisations. The cause has not been established.
- A purity test confirms what peptide is in a sample and how much. It does not check sterility, endotoxins or other contaminants, or whether the next vial matches.
First, what retatrutide legally is
Retatrutide is Eli Lilly's investigational triple agonist of the GLP-1, GIP and glucagon receptors. In an August 12, 2026 press release announcing six lawsuits, Lilly described it as an investigational molecule in phase 3 trials and stated that no medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world, and that it cannot be sold to consumers 1. FDA's page on unapproved GLP-1 drugs (content current as of October 1, 2026) says retatrutide and cagrilintide cannot be used in compounding under federal law, and that FDA has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide, falsely labelled 'for research purposes' or 'not for human consumption', directly to consumers with dosing instructions 2.
That is the frame for everything below: a product sold as retatrutide is not a licensed medicine with a manufacturer accountable for its contents. Our retatrutide hub covers the trials; this article covers what has turned up in the vials.
What buyer-submitted lab reports show
Buyers send vials to independent analytical laboratories, which return a certificate; our COA Decoder explains the identity, purity and quantity lines on one. Several websites collect these reports. On October 27, 2026, the largest aggregator we checked listed 4,650 retatrutide tests from 406 vendors, dated December 17, 2024 to October 21, 2026, and its displayed test history of 200 results showed 133 passes, 65 failures and 2 incomplete 3.
Passes and failures side by side tell you little about the market as a whole, and the reason is how the samples are chosen. Buyers decide which vials to send and which results to share. A seller can submit its own best batch; a buyer who suspects a problem is more likely to test. The laboratory verifies what is in the sample it receives, never where that sample came from, so the seller's name on a report is whatever the submitter declared. Our own lab-results database requires two independent sources before naming any party for exactly this reason 4. Aggregate pass rates from such reports are not a measure of the market; they are a measure of what people chose to test.
| Source of evidence | Who chose the sample | What it shows |
|---|---|---|
| Buyer-submitted lab reports, collected by testing aggregators | Buyers, who decide what to send and whether to publish | Thousands of reports; one aggregator's displayed test history of 200 shows 133 passes and 65 failures |
| Regulators and clinicians (Victoria, Australia) | Patients who became ill | Six cases of acute liver injury in the June alert, seven hospitalisations reported by August; a contaminant suspected, cause not established |
| Manufacturer (Lilly) | Lilly's own investigations | Six lawsuits; no retatrutide medicine approved anywhere |
| Peer-reviewed test purchases (semaglutide, 2024) | Researchers, buying as consumers | All vials probably substandard or falsified: content 29-39% above label, endotoxin 8.95 EU/mg in one vial |
Liver injury in Victoria, Australia
The clearest signal of harm comes from Australia. On June 19, 2026, Victoria's Chief Health Officer issued a health alert: since January 2026 there had been six cases of acute liver injury in Victoria in people who had used an unapproved peptide product labelled as Retatrutide, sold under names including Reta, R-10 and R-20. The alert said the toxic effects were possibly associated with a contaminant, that further testing of the products was under way, and it asked clinicians to be alert for abnormal liver function tests and to ask patients with compatible symptoms about peptide use 5.
On August 24, ABC News reported that seven Victorian patients had been hospitalised and that a liver transplant specialist had commissioned testing of the products patients used; she called a contaminated batch "purely a hypothesis at this stage", and the chief medical adviser of Australia's medicines regulator said the localised nature of the cases suggested a batch problem, adding that her comments did not come from an investigation. No test results were available 6. As of October 27, 2026 the alert page still showed its June 19 update, and we found no published laboratory result explaining the injuries 5. Lilly's published trial results, summarised on our hub, report mainly gastrointestinal side effects and a skin-sensation signal 7; whether these products contained retatrutide, something else, or a contaminant is the open question.
If you have used a product labelled retatrutide
Victoria's health department told people who had used these products and developed unusual or unexpected symptoms to seek medical care promptly, and suggested that anyone continuing to use them arrange a review with their GP to consider liver function tests; it also advised anyone who had bought the product not to use it. The symptoms it lists include tiredness, yellow eyes or skin, abdominal pain, dark urine, itchy skin and abnormal bruising 5.
Liver injury is not the only problem reported. In a 2026 case report from Edinburgh, a man with type 1 diabetes developed severe vomiting, diarrhoea, ketonaemia and acute kidney injury shortly after injecting an online product marketed as retatrutide; his partner, who took the same product, also had gastrointestinal symptoms, and a Shigella infection complicated the picture, so the authors could not establish causation. They urged clinicians to ask routinely about non-prescribed agents 8.
If you see a clinician, bring the vial or its packaging, and say what it was sold as, where it came from and when you used it. Doctors in Victoria were specifically asked to question patients about peptide use 5; volunteering it saves time. In the US, FDA's unapproved-GLP-1 page asks health care professionals and patients to report adverse events or quality problems to its MedWatch programme and lists the agency's drug information line 2.
What testing would actually settle the question
Better evidence is possible. The most useful would be test purchases by researchers or regulators, buying as ordinary customers across many sellers, and testing for identity, quantity, sterility and endotoxin, as the 2024 semaglutide study did on a small scale 9. Results of the product testing under way in Victoria, once published, could show whether the liver injuries trace to retatrutide, a substitute or a contaminant 5 6. Until such evidence exists, buyer-submitted certificates remain the main data, with all the selection problems described above.
What researcher-bought samples found for a related drug
The most rigorous kind of testing is a test purchase: researchers buy as ordinary consumers, so the sample is not chosen by the seller. A PubMed search on October 27, 2026 (retatrutide with counterfeit, falsified, test purchase, purity, illegal online, unregulated or liver injury) returned four records, none a test purchase. The closest is a 2024 study of semaglutide sold without prescription online. Of six attempted purchases, three injection vials arrived and three branded pens never did, lost to delivery scams. All three vials were judged probably substandard or falsified: they failed more than half of the visual inspection criteria, contained 29% to 39% more semaglutide than labelled, and one measured 8.95 EU/mg of endotoxin, a bacterial toxin that can cause fever and inflammation if injected (test-purchase study) 9.
That study illustrates what buyer-submitted purity reports usually miss: the peptide was the right one and free of peptide-like impurities, yet the products were overdosed and contaminated with endotoxin.
What a passing test does and does not tell you
A typical certificate of analysis for a gray-market peptide answers two questions: is the right molecule present, and how pure and how much is it? A passing result is genuinely useful: it rules out an empty or wrong vial for that sample. It does not show sterility, endotoxin levels, heavy metals or solvent residues unless those were specifically tested. It applies to one vial from one batch, not the next order. And it cannot tell you whether the dosing a seller suggests is safe; retatrutide's doses have been tested only in Lilly's trials.
Our guide to spotting a fake COA covers forged certificates, and our COA Decoder explains what each line on a real one means. Even a genuine, passing certificate is a statement about a sample, not a guarantee about a product.
The names are part of the problem
Products sold as retatrutide often avoid the name. Victoria's alert listed 'Reta', 'R-10' and 'R-20' 5, and labels such as 'GLP-3' are also used; our guide to GLP-3 and other gray-market names decodes them. A label that avoids the drug's name makes the product harder for regulators, platforms and buyers to identify.
Enforcement so far
FDA's actions, as listed on its unapproved-GLP-1 page, include warning letters to telehealth companies marketing retatrutide, to active-ingredient distributors selling it to compounders and to an outsourcing facility repackaging it 2. Lilly's August 2026 lawsuits targeted compounding pharmacies, medical spas and online sellers claiming 'research use only', and the company called on social media and e-commerce platforms, card companies, payment processors and shipping companies to cut off the trade 1. Our report on gray-market payments and testing spend looks at how the market has responded.
Questions to ask before trusting a retatrutide vial
- Is this a Lilly clinical trial? (Lilly says no retatrutide medicine is approved anywhere and that it cannot be sold to consumers.)
- Who chose the sample on the certificate, and is it for this exact batch?
- Does the certificate test identity, quantity, sterility and endotoxin, or only identity and purity?
- Is the product sold under the drug's name, or under a code like 'Reta', 'R-10' or 'GLP-3'?
- Would an approved GLP-1 or GIP/GLP-1 drug, prescribed and monitored, meet the same goal? Our Approved-Alternative Finder lists them.
The bottom line
Testing has made the retatrutide gray market look more scientific than it is. Thousands of lab reports exist, including outright failures, but they are chosen by buyers and sellers, verify only the sample sent, and rarely check sterility or contaminants. In Victoria, Australia, products labelled retatrutide have been linked to acute liver injury (seven hospitalisations by ABC News's August count), cause unknown. No retatrutide medicine is approved anywhere. A passing certificate on one vial is not evidence that the next one is safe.
Frequently asked questions
Is retatrutide sold online real?
Buyer-submitted lab reports include both passes and failures; one aggregator's displayed history of 200 tests shows 133 passes and 65 failures. No retatrutide medicine is approved anywhere.
Can a lab test prove retatrutide is safe?
No. A typical certificate confirms identity and purity of one sample. It usually does not test sterility, endotoxin or contaminants, and it says nothing about the next batch.
Has fake retatrutide hurt anyone?
Victoria's health department reported six cases of acute liver injury in people who had used products labelled retatrutide by June 2026, possibly associated with a contaminant, and ABC News reported seven hospitalisations in August. The cause has not been established.
Is retatrutide legal to buy?
It is not approved anywhere. FDA says it cannot be compounded and has warned companies selling 'research purposes' versions directly to consumers. Lilly says it is in phase 3 trials and cannot be sold to consumers.
What names is fake retatrutide sold under?
Victoria's alert listed 'Reta', 'R-10' and 'R-20'. Labels such as 'GLP-3' are also used; our guide to gray-market names decodes them.
Related on Grey Peptides
Sources
- Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (press release announcing six lawsuits). August 12, 2026; re-read October 27, 2026.
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (sections on retatrutide and cagrilintide, products sold 'for research purposes', FDA actions and reporting). Content current as of October 1, 2026; re-read October 27, 2026. FDA
- Largest public aggregator of buyer-submitted retatrutide lab reports checked (not linked or named because it ranks sellers): retatrutide page showing 4,650 tests across 406 vendors, December 17, 2024 to October 21, 2026, and a test-history summary of 200 tests: 133 pass, 65 fail, 2 incomplete. Re-read October 27, 2026 (October 3 read: 4,367 tests, 378 vendors).
- Grey Peptides lab-results database, naming rule settled October 1, 2026: one source suffices only if it obtained the sample itself; two independent sources are required for buyer-submitted reports.
- Victorian Department of Health. Health alert: Toxicity linked to unapproved peptide product labelled Retatrutide. Issued June 19, 2026 by the Chief Health Officer (page updated June 19, 2026); re-read October 27, 2026.
- ABC News (Australia). Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage. August 24, 2026; re-read October 27, 2026.
- Grey Peptides encyclopedia entry and hub for retatrutide: trial safety summary (gastrointestinal effects and dysesthesia signal). Re-read October 27, 2026.
- Branine, N. (2026). Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus, 18(8), e115260. PMID: 42669023
- Ashraf, A. R., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead